Acute pulmonary embolism (APE) is a critical condition characterized by high mortality and morbidity, primarily caused by the obstruction of pulmonary artery vessels due to various types of emboli such as blood clots, fat droplets, air bubbles, intravenous drug particles, and amniotic fluid. The resultant blockage leads to cardiac insufficiency and significant respiratory symptoms. In athletes, particularly those with musculoskeletal injuries, the management of APE poses unique challenges due to their specific physiological and health requirements. This study specifically focuses on the efficacy analysis of low-dose and standard-dose alteplase in the thrombolytic treatment of APE in athletic patients with musculoskeletal injuries. Alteplase, a tissue plasminogen activator, plays a crucial role in dissolving the obstructive clots in the pulmonary artery, thereby alleviating the symptoms of pulmonary thromboembolism (PTE) – a condition marked by the obstruction of the pulmonary artery or its branches by a thrombus originating from the venous system or the right heart, leading to compromised pulmonary circulation and respiratory dysfunction. The investigation revolves around comparing the effects of low-dose and standard-dose alteplase, considering both the efficacy in resolving pulmonary emboli and the safety profile, which is particularly pertinent in athletes who are prone to bleeding due to musculoskeletal injuries. The study aims to provide insights into the optimal thrombolytic therapy for athletic patients, balancing the urgent need for effective clot dissolution with the risk of exacerbating injury-related complications. This research is pivotal in guiding the treatment protocols for acute pulmonary embolism in a specialized cohort of patients, enhancing both their immediate and long-term health outcomes.